Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study
Fuente:
Wiley Open Access
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Veröffentlicht: |
Wiley
2025
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1867003870611243008 |
|---|---|
| author | Rocío López Mármol José Alejandro Ávila Cabreja Teresa de Haro Romero Catalina de Paco Matallana Olga Ocón Hernández Otilia González‐Vanegas Pilar Carretero Lucena María Paz Carrillo Juan Luis Delgado Valeria Rolle Uzay Gormus Liza Oraha María M. Gil Francisca S. Molina |
| author_facet | Rocío López Mármol José Alejandro Ávila Cabreja Teresa de Haro Romero Catalina de Paco Matallana Olga Ocón Hernández Otilia González‐Vanegas Pilar Carretero Lucena María Paz Carrillo Juan Luis Delgado Valeria Rolle Uzay Gormus Liza Oraha María M. Gil Francisca S. Molina Rocío López Mármol José Alejandro Ávila Cabreja Teresa de Haro Romero Catalina de Paco Matallana Olga Ocón Hernández Otilia González‐Vanegas Pilar Carretero Lucena María Paz Carrillo Juan Luis Delgado Valeria Rolle Uzay Gormus Liza Oraha María M. Gil Francisca S. Molina |
| collection | Wiley Open Access |
| contents | Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study Rocío López Mármol José Alejandro Ávila Cabreja Teresa de Haro Romero Catalina de Paco Matallana Olga Ocón Hernández Otilia González‐Vanegas Pilar Carretero Lucena María Paz Carrillo Juan Luis Delgado Valeria Rolle Uzay Gormus Liza Oraha María M. Gil Francisca S. Molina Acta Obstetricia et Gynecologica Scandinavica AbstractIntroductionOur objective was to compare the predictive performance of the Fetal Medicine Foundation (FMF) competing‐risk model for preterm preeclampsia (PE) screening using placental growth factor (PlGF) measurements obtained at 11–13+6 weeks versus before 11 weeks of gestation.Material and MethodsThis multicenter prospective cohort study included women with singleton pregnancies attending their routine first‐trimester assessment (11+0 to 13+6 weeks) in four hospitals across Spain from 2021 to 2023. Maternal characteristics, biophysical parameters (mean arterial pressure and uterine artery pulsatility index), and biochemical markers (PlGF measured twice in each woman, before 11 weeks and between 11 and 13+6 weeks) were assessed. Risk assessment for preterm PE was estimated by the FMF algorithm. Predictive performance was evaluated by comparing detection rates (DR) at different fixed screen‐positive rates (SPR), area under the receiver‐operating characteristic curve (AUROC), and calibration plots. Statistical adjustments were made to account for prophylactic aspirin use.ResultsThe study population comprised 3448 women, including 19 (0.55%) who developed preterm preeclampsia and 47 (1.36%) who developed term preeclampsia. At 10% SPR, the detection rates (adjusted for aspirin use) were highest for the model incorporating PlGF between 11 and 13+6 weeks (72.9%; 95% CI, 42.2%–90.9%), compared to models with PlGF before 11 weeks (66.4%; 95% CI, 39.9%–85.4%) and without PlGF (66.0%; 95% CI, 39.3%–85.3%). Similar trends were observed at higher SPR thresholds. The best discrimination (AUROC: 0.863; 95% CI, 0.754–0.971) and calibration were also achieved by the model using PlGF between 11 and 13+6 weeks.ConclusionsPlGF measured before 11 weeks did not improve preterm PE screening performance. Due to the small number of cases, further validation is needed. Maternal and biophysical markers remain a viable alternative when PlGF is unavailable. 10.1111/aogs.70026 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| doi_str_mv | 10.1111/aogs.70026 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_aogs_70026 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study Rocío López Mármol José Alejandro Ávila Cabreja Teresa de Haro Romero Catalina de Paco Matallana Olga Ocón Hernández Otilia González‐Vanegas Pilar Carretero Lucena María Paz Carrillo Juan Luis Delgado Valeria Rolle Uzay Gormus Liza Oraha María M. Gil Francisca S. Molina Acta Obstetricia et Gynecologica Scandinavica Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study Rocío López Mármol José Alejandro Ávila Cabreja Teresa de Haro Romero Catalina de Paco Matallana Olga Ocón Hernández Otilia González‐Vanegas Pilar Carretero Lucena María Paz Carrillo Juan Luis Delgado Valeria Rolle Uzay Gormus Liza Oraha María M. Gil Francisca S. Molina Acta Obstetricia et Gynecologica Scandinavica AbstractIntroductionOur objective was to compare the predictive performance of the Fetal Medicine Foundation (FMF) competing‐risk model for preterm preeclampsia (PE) screening using placental growth factor (PlGF) measurements obtained at 11–13+6 weeks versus before 11 weeks of gestation.Material and MethodsThis multicenter prospective cohort study included women with singleton pregnancies attending their routine first‐trimester assessment (11+0 to 13+6 weeks) in four hospitals across Spain from 2021 to 2023. Maternal characteristics, biophysical parameters (mean arterial pressure and uterine artery pulsatility index), and biochemical markers (PlGF measured twice in each woman, before 11 weeks and between 11 and 13+6 weeks) were assessed. Risk assessment for preterm PE was estimated by the FMF algorithm. Predictive performance was evaluated by comparing detection rates (DR) at different fixed screen‐positive rates (SPR), area under the receiver‐operating characteristic curve (AUROC), and calibration plots. Statistical adjustments were made to account for prophylactic aspirin use.ResultsThe study population comprised 3448 women, including 19 (0.55%) who developed preterm preeclampsia and 47 (1.36%) who developed term preeclampsia. At 10% SPR, the detection rates (adjusted for aspirin use) were highest for the model incorporating PlGF between 11 and 13+6 weeks (72.9%; 95% CI, 42.2%–90.9%), compared to models with PlGF before 11 weeks (66.4%; 95% CI, 39.9%–85.4%) and without PlGF (66.0%; 95% CI, 39.3%–85.3%). Similar trends were observed at higher SPR thresholds. The best discrimination (AUROC: 0.863; 95% CI, 0.754–0.971) and calibration were also achieved by the model using PlGF between 11 and 13+6 weeks.ConclusionsPlGF measured before 11 weeks did not improve preterm PE screening performance. Due to the small number of cases, further validation is needed. Maternal and biophysical markers remain a viable alternative when PlGF is unavailable. 10.1111/aogs.70026 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| title | Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study |
| topic | Acta Obstetricia et Gynecologica Scandinavica |
| url | https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.70026 |